Journal Article10.1016/J.PHARMTHERA.2005.06.006
Targeting memory Th2 cells for the treatment of allergic asthma.
55
TL;DR: An overview of therapeutic strategies targeting Th2 memory cells in allergic asthma is presented, emphasizing Th2 generation, differentiation, activation, migration, effector function, and survival.
read more
About: This article is published in Pharmacology & Therapeutics. The article was published on 01 Jan 2006. The article focuses on the topics: Effector.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
A novel subset of CD4+ TH2 memory/effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma
Yui Hsi Wang,Kui Shin Voo,Bo Liu,Chun Yu Chen,Burcin Uygungil,William Spoede,Jonathan A. Bernstein,David P. Huston,Yong-Jun Liu,Yong-Jun Liu +9 more
TL;DR: Memory CD4+ T cells that produce both Th2 and Th17 cytokines are increased in the blood of patients with atopic asthma and in the lungs of asthmatic mice, where they contribute to inflammation.
Efficacy and mechanisms of action of traditional Chinese medicines for treating asthma and allergy
Xiu-Min Li,L.L. Brown +1 more
TL;DR: Evidence from clinical studies supports beneficial effects of TCM herbal therapy on asthma, and strong preclinical study data suggest the potential efficacy of food allergy herbal formula-2 for food allergy.
Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35.
Chiung-Hui Huang,Evelyn Xiu Ling Loo,I-Chun Kuo,Gim Hooi Soh,Denise L.M. Goh,Bee Wah Lee,Kaw Yan Chua +6 more
TL;DR: It is suggested that IL-35 could be a potential therapeutic target for allergic asthma through its attenuating effects on allergen-specific CD4+ memory/effector Th2 cell-mediated airway inflammation.
Ursolic acid, a potential PPARγ agonist, suppresses ovalbumin-induced airway inflammation and Penh by down-regulating IL-5, IL-13, and IL-17 in a mouse model of allergic asthma.
TL;DR: The data suggest the therapeutic mechanism of ursolic acid in asthma is based on reductions of Th2 cytokines, ovalbumin-specific IgE production, and eosinophil infiltration via the Th2-GATA-3, STAT6, and IL-17-NF-κB pathways.
101
Monoclonal antibodies for the treatment of asthma.
TL;DR: A number of monoclonal antibody based drugs have been clinically tested in asthma including anti-IL-5, anti- IL-4, anti -IL-13,Anti-TNFα, anti,CCR3, anti/CCR4 and anti-OX40L and these studies provide information on patient stratification and asthma pathology.
77
References
A novel transcription factor, T-bet, directs Th1 lineage commitment.
Susanne J. Szabo,Sean T Kim,Gina L. Costa,Xiankui Zhang,C. Garrison Fathman,Laurie H. Glimcher +5 more
TL;DR: T-bet initiates Th1 lineage development from naive Thp cells both by activating Th1 genetic programs and by repressing the opposing Th2 programs, as evidenced by the simultaneous induction of IFNgamma and repression of IL-4 and IL-5.
3.8K
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Yvette Latchman,Clive Wood,Tatyana Chernova,Divya Chaudhary,Madhuri Borde,Irene Chernova,Yoshiko Iwai,Andrew J. Long,Julia A. Brown,Raquel A. Nunes,Edward A. Greenfield,Karen Bourque,Vassiliki A. Boussiotis,Laura L. Carter,Beatriz M. Carreno,Nelly Malenkovich,Hiroyuki Nishimura,Taku Okazaki,Tasuku Honjo,Arlene H. Sharpe,Gordon J. Freeman +20 more
TL;DR: These studies show overlapping functions of PD-L1 andPD-L2 and indicate a key role for the PD- L–PD-1 pathway in regulating T cell responses.
3.1K
Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma
Douglas S. Robinson,Qutayba Hamid,Sun Ying,Anne Tsicopoulos,J. Barkans,Andrew Bentley,Christopher Corrigan,Stephen R. Durham,A. B. Kay +8 more
TL;DR: Atopic asthma is associated with activation in the bronchi of the interleukin-3, 4, and 5 and GM-CSF gene cluster, a pattern compatible with predominant activation of the TH2-like T-cell population.
2.9K
Interleukin-13: Central Mediator of Allergic Asthma
Marsha Wills-Karp,Jackie Luyimbazi,Xueying Xu,Brian Schofield,Tamlyn Neben,Christopher L. Karp,Debra D. Donaldson +6 more
TL;DR: In this paper, the type 2 cytokine IL-13, which shares a receptor component and signaling pathways with IL-4, was found to be necessary and sufficient for the expression of allergic asthma.
2.7K
•Journal Article
Interleukin-13: Central mediator of allergic asthma
Marsha Wills-Karp,Jackie Luyimbazi,Xueying Xu,Brian Schofield,Tamlyn Neben,Christopher L. Karp,Debra D. Donaldson +6 more
TL;DR: In this article, the type 2 cytokine IL-13, which shares a receptor component and signaling pathways with IL-4, was found to be necessary and sufficient for the expression of allergic asthma.
2.4K